Novartis announced on September 4 that its closely watched Phase 3 Lp(a)HORIZON clinical trial evaluating pelacarsen for cardiovascular disease missed its primary endpoint.
Clinical Trial Results and Biomarker Disconnect
The Phase 3 trial failure exposes a major strategic dilemma for cardiovascular researchers studying lipoprotein(a), commonly known as Lp(a). Pelacarsen successfully lowered Lp(a) levels by up to 80 percent in earlier Phase 2 evaluations. However, that dramatic biomarker drop failed to translate into a measurable reduction in hard cardiovascular outcomes for patients in the Phase 3 study, according to Novartis.
This gap between surrogate biomarker reduction and clinical outcomes creates a fundamental hurdle for drug developers. Regulatory agencies and trial sponsors must now re-examine whether lowering Lp(a) is a reliable surrogate endpoint for building large cardiovascular outcome programs, or if researchers need to reconceive baseline thresholds and target populations before launching future trials.
Financial Impact on Ionis Pharmaceuticals
The trial’s failure delivers an immediate financial blow to Ionis Pharmaceuticals under the companies’ 2019 licensing agreement. Ionis stood to receive tiered royalties in the mid-teens to low 20 percent range on net sales, alongside $650 million in development, regulatory, and commercial milestones. The unsuccessful outcomes trial eliminates the commercial royalty stream entirely and voids milestone payments tied directly to regulatory approval and commercial launch. Ionis retains development milestones already collected prior to the trial readout, but future revenue streams tied to the drug’s commercialization are gone.
After-Hours Market Reaction
Financial markets reacted swiftly to the clinical setback. According to financial tracking reports from Yahoo Finance, shares of Novartis (NVS), Ionis Pharmaceuticals (IONS), and Amgen (AMGN) dropped in after-hours trading immediately following the public announcement.
Future Outlook for Lp(a) Therapeutics
Researchers across the pharmaceutical industry are now awaiting the full dataset release from Novartis to parse subgroup analyses, baseline Lp(a) thresholds, and absolute event rates in the placebo arm. These detailed disclosures will determine whether the underlying therapeutic hypothesis is flawed or if the trial enrolled patient populations at the incorrect baseline Lp(a) levels. Competing antisense and small-molecule programs currently in development rely on these findings to decide whether to adjust their own late-stage clinical trial designs.